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Trichomonas vaginalis is the causative agent of trichomoniasis, the most common nonviral STD world-
wide. This infection can lead to severe health conditions, especially when women are affected. Metro-
nidazole and tinidazole are the only choices of treatment. In this sense, natural bioactive compounds
against T. vaginalis are an interesting approach in the search for more efﬁcient therapies. Herein,
amaurocine, a 12 kDa protein, produced by the mushroom Amauroderma camerarium was puriﬁed and
tested against T. vaginalis, including two fresh clinical isolates. Amaurocine presented MIC values at
2.6 mM against the ATCC isolate 30236, and 5.2 mM against the fresh clinical isolates, TV-LACH1 and TV-
LACM2. Furthermore, besides increasing human neutrophils nitric oxide release, amaurocine presented a
low toxicity toward those cells, suggesting it exerts a proinﬂammatory character.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Trichomonas vaginalis is a ﬂagellated protozoan, which infectsthe urogenital tract. It is the most common nonviral sexually
transmitted disease (STD) worldwide, with an estimation of 276
million new cases per year (WHO, 2012). Trichomoniasis can occur
asymptomatically, especially in men, or present acute inﬂamma-
tory vaginitis in women (Poole and McClelland, 2013). This infec-
tion has been associated to premature birth (Cotch et al., 1997),
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prostate cancer (Viikki et al., 2000; Sutcliffe et al., 2012), as well as
pelvic inﬂammatory disease (Cherpes et al., 2006). Additionally,
there are strong evidences in the literature that T. vaginalis in-
creases the susceptibility to the human immunodeﬁciency virus
(HIV) (Mason et al., 2005; Kissinger and Adamski, 2013). Metroni-
dazole and tinidazole, both belonging to the 5-nitroimidazoles
class, are the only drugs recommended by the Food and Drug
Administration (FDA, USA) for the treatment of human trichomo-
niasis (Helms et al., 2008). However, the occurrence of common
adverse reactions, carcinogenic and teratogenic effects as well as
resistant isolates of T. vaginalis has been reported (Müller et al.,
1988; Upcroft et al., 2006).
Although its high incidence, this disease is not included in any
control and surveillance program, being classiﬁed as a neglected
infection (Van Der Pol, 2007; Secor et al., 2014; Taylor, 2014). The
pathogen affects mostly the low-income population (Goodhew and
Secor, 2013), and it is not a surprise that the efforts on the research
for new drugs against this protozoan are concentrated in the aca-
demic ﬁeld. Screenings against T. vaginalis have been performed
using plant material (Frasson et al., 2012; Vieira et al., 2011; Cargnin
et al., 2013; Rocha et al., 2012) marine microorganisms (Gehrig and
Efferth, 2009; Watts et al., 2010; Scopel et al., 2013) as well as
natural and synthetic compounds (Crowell et al., 2004; Giordani
et al., 2009, 2010; 2012; Innocente et al., 2014), including a chem-
ical library comprising molecules already approved for human use
(Goodhew and Secor, 2013). Those efforts, however, did not lead to
new therapies yet.
There are a number of studies aiming antiparasitic activity of
molecules produced by Basidiomycotina fungi (Adams et al., 2010;
Jin and Zjawiony, 2006; Cota et al., 2008). Those organisms are
known to synthetize secondary metabolites, ranging from very
simple to high complex structures, which show a diversity of bio-
logical activities with medical application (Spiteller, 2008).
Therefore, we performed a screening using extracts from the
Basidiomycotina fungi Amauroderma camerarium, for compounds
with anti-T. vaginalis activity. Three T. vaginalis isolates, including
one fromATCC and two fresh clinical isolates were employed in this
work. A 12 kDa protein showing the aforementioned property, was
puriﬁed, sequenced and further named amaurocine. In addition,
the immunomodulatory activity of amaurocine was partially
evaluated.
2. Materials and methods
2.1. Culture of T. vaginalis
Three T. vaginalis isolates, ATCC 30236 and the fresh clinical
isolates TV-LACH1 and TV-LACM2, were used in this study.
Trichomonads were cultured axenically in vitro in trypticase-yeast
extract-maltose (TYM) medium, pH 6.0, supplemented with 10%
(v/v) heat-inactivated bovine serum, and incubated at 37 ± 0.5 C
(Diamond, 1957). Organisms in the logarithmic phase of growth
and exhibiting more than 95% viability and normal morphology
were harvested, centrifuged, washed three times with PBS buffer
and suspended in new TYM medium for assays.
2.2. Sampling, isolation and identiﬁcation of A. camerarium
Amauroderma camerarium was collected in S~ao Francisco de
Paula, Rio Grande do Sul, Brazil. To mycelial isolation, small tissue
fragments from an inner section of a fruiting bodywere excised and
placed in Petri dishes containing Potato Dextrose Agar (PDA, Difco)
and incubated at 25 C, during 15 days. One specimen was sent to
the Department of Botany, located at the Universidade Federal doRio Grande do Sul (UFRGS) to taxonomic classiﬁcation. The culture
was maintained in malt extract agar (MEA), at 25 C.
2.3. Production of the active compound
The mycelia of A. camerarium was grown in ﬂasks containing
50 mL of malt extract broth (MEB), supplemented with different
nitrogen sources, as follows: (a) 3% malt extract broth (MEB), (b)
MEB supplementedwith 3 g/L of KNO3, (c) MEB supplementedwith
3 g/L of (NH4)2SO4 and (d) MEB supplemented with 3 g/L of
peptone. All employed media had their pH adjusted to 7.0.
Fermentation was carried out during 14, 21 and 28 days, in static
conditions. After ﬁltration to fungal biomass removal, the super-
natant was freeze-dried and the concentration adjusted to 100 mg/
mL. Therefore, this screening approach counted with 12 aqueous
extracts, which were tested against the ATCC 30236 T. vaginalis
isolate.
2.4. Anti-T. vaginalis activity assay
T. vaginalis ATCC 30236 (5.0  104 trophozoites/mL in TYM
medium) was incubated together with the obtained extracts
(20 mg/mL), in 96 well microtiter plates, at 37 C, in a ﬁnal volume
of 200 mL. After 24 h, trichomonads viability was accessed using a
resazurin assay, as previously described (Duarte et al., 2009). Pos-
itive and negative references consisted in non-inoculated media
and media containing metronidazole. These experiments were
executed using three independent cultures and in triplicate.
2.5. Puriﬁcation of the active compound
The active extracts were subjected to dialysis separation against
distilled water, using a membrane with cut-off of 10 kDa (Sigma-
eAldrich). Dialysis was performed at 4 C during 7 days and the
distilled water changed each 24 h. Protein fractions with molecular
weight higher than 10 kDa and lower than 10 kDa were tested
against T. vaginalis, at a concentration of 20 mg/mL.
The fraction bearing proteins >10 kDa was applied to an ion-
exchange HiTrap Q HP 5 mL column using TriseHCl buffer
(20 mM, pH 7.5, 1.0 mL/min) in a FPLC system (GE Healthcare).
Retained proteins were eluted with a linear NaCl-gradient
(0e1.0 M) in the same buffer, resulting in 38 fractions of 1.5 mL.
Each fractionwas tested against T. vaginalis as speciﬁed above and a
control of the buffer was performed. The active fractions were
pooled, concentrated in a 3.0 kDa centrifugal ﬁlter device (Amicon®
Ultra e Millipore) and applied onto a Superdex 75, 24 mL gel-
ﬁltration column (0.5 mL/min), previously equilibrated in
TriseHCl buffer (20 mM, pH 7.5) and calibrated with molecular
weight standards (Gel ﬁltration calibration kit low molecular
weight, GE Healthcare). This fractioning resulted in 34 fractions of
1.0 mL, which were tested against T. vaginalis. Protein content of
eluted fractions was monitored by absorbance reading at 280 nm
and electrophoresis on sodium dodecyl sulfate-polyacrylamide gels
(SDS-PAGE) under denaturing conditions (Laemmli, 1970). Elec-
trophoresis was performed using a Bio-Rad Mini-Protean Cell II
unit. Resolving and stacking gels were 18% and 5% polyacrylamide,
respectively. The active fraction was dried and suspended in water
at a protein concentration of 500 mg/mL (stock solution), dosed by
Biuret reaction (Gornall et al., 1949) for the following experiments.
2.6. Protein sequencing
The 12 kDa-isolated protein with anti-T. vaginalis activity was
treated with trypsin and sequenced by mass spectrometry. Sample
was prepared using the protocol of Schevchenko et al. (1996) with
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SDS-PAGE (18%). The gel was stained with Coomassie Brilliant Blue
G-250 and destained in 50% methanol, 5% acetic acid in milli-Q
water. Protein band was excised and completely destained in the
same solution (overnight). Gel piece was dehydrated in acetonitrile
(200 mL) for 5 min and dried in Speed Vac (Thermo) for 2e3 min.
Reduction of disulﬁde bonds was achieved by incubation with
10 mM dithiotreitol (DTT) for 30 min. After removal of DTT, alkyl-
ation reaction was done with 50 mM iodoacetamide solution
(30 mL) for 30min. Iodoacetamidewas removed and the gel washed
with 10 mM ammonium bicarbonate (100 ml) for 10 min and
dehydrated with ACN (200 mL) for 5 min. These two last steps were
repeated and the gel completely dried in Speed Vac. Dried gel piece
was incubated with 20 ng/ml sequencing-grade trypsin (Promega;
30 mL) in 50 mM ammonium bicarbonate for 10 min, before the
excess of enzyme solution not absorbed by the gel be removed.
Ammonium bicarbonate (50 mM, 20 mL) was added and incubated
at 37 C by 24 h. After washing with ammonium bicarbonate
(100 mM), the tryptic-digested amaurocine peptides were extrac-
ted 2 times with 5% formic acid, 50% ACN in water (30 mL) for
10 min.
For MS/MS analyses, peptides were suspended in 0.1% formic
acid (50 ml), and separated in a C18 capillary column
(15 cm  75 mm, Symetric C18, Waters). Mobile phase A was 0.1%
formic acid in 2% ACN, and mobile phase B was 0.1% formic acid in
99% ACN, ﬂow 0.6 mL/min, run of 30 min. Eluted peptides were
analyzed online with an ESI-Q-TOF mass spectrometer (Micro,
Micromass, Waters), equipped with a nanoﬂow source. The in-
strument settings were 3 kV for the spray voltage, 100 V for the
cone voltage, 100 C for the source temperature, and cone gas at
30 L/h. Spectra were collected at the positive-ion mode. The
LCeMS/MS data were analyzed using the MASCOT 2.1 search en-
gine (Matrix Science Inc.) through the Swiss-Prot or NCBI protein
sequence data bank.
2.7. Minimal inhibitory concentration (MIC)
The puriﬁed 12 kDa protein with antiparasitc activity, named
amaurocine, was serial diluted in a 96-well microtiter plate, with a
ﬁnal concentration range from 0.083 mM to 10 mM. The plates were
then inoculatedwith T. vaginalis isolates and allowed to stand at 37
C, during 24 h. Metronidazole was used as a positive reference, in a
concentration range of 2.9 mMe580 mM. Trophozoites viability was
determined using the resazurin method (Duarte et al., 2009).
2.8. Neutrophils isolation
Human neutrophils were isolated as described (Boyum, 1968),
with some modiﬁcations. Initially, 10 mL of heparinized human
blood. Blood donors were healthy volunteers who signed speciﬁc
form for consent to participate in the study. The Universidade
Federal do Rio Grande do Sul Ethical Committee approved docu-
ments, procedures and project under authorization number 19346.
The blood was centrifuged (250  g, 10 min, 24 C). The resulting
platelet-rich plasma supernatant was discarded. Leukocytes were
obtained following erythrocyte sedimentation in 2% Dextran T-500
and centrifuged (525  g, 20 min, 24 C) through layering on His-
topaque 1077 (SigmaeAldrich). The supernatant was discarded and
the red blood cells were lysed by hypotonic lysis for 15 min. Lyse
was stopped adding 1.0 mL of Hanks (HBSS) 10 solution. The tube
was centrifuged (1000  g, 5 min, 24 C) and the supernatant was
discarded. The pellet was resuspended in 2.0 mL of RPMI-1640
medium supplemented with 10% of fetal bovine serum and
10 mM HEPPES buffer. Neutrophils were counted in hemocytom-
eter and the viability was assessed by Trypan Blue exclusion. Thepurity of neutrophils was conﬁrmed morphologically (>95%) and
examined by phenotypic analysis using ﬂow cytometry (FACSCali-
bur, BD Bioscience) and Cell Quest software, after staining with
ﬂuorescein isothiocyanate (FITC)-conjugated anti-CD45, anti-CD15,
anti-CD8 antibodies and phycoerythrin (PE)-conjugated anti-CD14,
anti-CD22, anti-CD3 and anti-CD4 antibodies (BD Bioscience).2.9. Nitrite (NO) release from neutrophils
NO release from neutrophils was evaluated under four treat-
ments in 96- well microtiter plates, in a ﬁnal volume of 200 mL, as
follows: (i) 2.0  105 neutrophils/mL in pure RPMI-1640 medium;
(ii) 2.0 105 neutrophils/mL and 2.0 104 trophozoites/mL mixing
both media, RPMI-1640 and TYM; (iii) 2.0  105 neutrophils/mL
together with 5.2 mMof puriﬁed protein in RPMI-1640medium and
(iv) 2.0 105 neutrophils/mL, together with 2.0 104 trophozoites/
mL and 5.2 mM of the puriﬁed protein. After 24 h incubation, the
cell-free culture supernatants were collected and immediately
subjected to NO quantiﬁcation, using a Griess reagent (Sigma-
eAldrich) in accordance to the manufacturer instructions.3. Results
3.1. Screening for anti-T. vaginalis compounds
Our screening approach showed that aqueous extracts obtained
after 21 and 28 days of fungal fermentation inhibited T. vaginalis
growing. The highest activity was observed within A. camerarium
cultivation during 28 days, in the medium with KNO3 supplemen-
tation. Here, trophozoites viability decreased in 76%, while among
the remaining extracts, inhibition was quantiﬁed between 50% and
20%. Therefore, this condition was employed in order to produce
the active metabolite in higher amounts for further investigations.3.2. Antiparasitic compound characterization and puriﬁcation
After dialysis, both portions from the cell-free supernatant with
molecular weight higher than 10 kDa (portion A), and lower than
10 kDa (portion B), were tested against T. vaginalis ATCC 30236.
Here, the portion A, bearing molecules of molecular weight higher
than 10 kDa resulted in an antiparasitic activity of 76%. To conﬁrm
the anti-trichomonads metabolite proteic character, proteins of
portion A were incubated with proteinase K, before to be tested
against T. vaginalis, resulting in a complete loss of the expected
activity (data not shown). Portion A was then applied to an ion-
exchange chromatography and the most active fractions were
eluted at high NaCl concentration (~1 M), pooled, concentrated and
loaded into the gel-ﬁltration column. One major peak was obtained
with this separation procedure which correlates with the anti-
T. vaginalis activity (Fig. 1a and b). The pure grade of this prepara-
tion was conﬁrmed by a silver stained SDS-PAGE gel (Fig. 1c),
yielding a 12 kDa protein, named here amaurocine.3.3. Amaurocine sequencing
The LCeMS/MS spectra analysis was performed using MS/MS
ion search tool of MASCOT 2.1 search engine (Matrix Science Inc.)
through the Swiss-Prot protein sequence database. This analysis
resulted in 39 peptide sequences (Supplementary Table 1) and
some of these peptides match to the Ajellomyces dermatitidis
SLH14081 ATP-dependent RNA helicase, MAK5 (Accession
XM_002627324.1).
Fig. 1. Overlay plot of (a) the analytical chromatogram (full line) of ion-exchange chromatography, the salt gradient (dashed line) and the percentage of T. vaginalis grow inhibition
(bars) of 1.5-mL fractions collected at 1.5-min intervals; (b) the analytical chromatogram (full line) of gel ﬁltration chromatography, and the percentage of T. vaginalis grow inhibition
(bars) of 1.0 -mL fractions collected at 2-min intervals and (c) Silver stained SDS-PAGE gel showing the pure grade of the active fraction after the gel-ﬁltration chromatography.
Molecular weight markers (MW) were run at lane 1 (kDa); lane 2 shows a single protein band.
Fig. 2. NO release from neutrophils (2 bars at the left side) and neutrophils and
T. vaginalis in the same incubation (2 bars at the right side). Black bars indicate the NO
release with no addition of amaurocine (5.2 mM) and gray bars indicate the NO release
with addition of amaurocine (5.2 mM). The asterisk indicate signiﬁcative difference
between the NO release from each treatment (neutrophils with addition of amaur-
ocine, T. vaginalis-stimulated neutrophils with or no addition of amaurocine) and NO
release from control (neutrophils) (t test, p < 0.01). Signiﬁcant difference was found
when NO release from neutrophils (a) was compared with NO release from T. vaginalis-
stimulated neutrophils with addition of amaurocine (b) (t test, p < 0.05).
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The MICs for amaurocine were evaluated against three
T. vaginalis isolates, resulting in 2.6 mM against the ATCC 30236
isolate, and 5.2 mM against the fresh clinical isolates TV-LACH1 and
TV-LACM2. Metronidazole MICs against those organisms were
determined as 8.0 mM, 4.56 mM and 580 mM, respectively.
3.5. Human neutrophils response towards amaurocine
A NO release assay was used in order to access amaurocine ac-
tion on human neutrophils. After 24 h of incubation together with
the protein, neutrophils remained viable (87.4 ± 3.8%), revealing a
very slight cytotoxicity against those cells. Furthermore, amaur-
ocine increased NO release by neutrophils both in the presence and
absence of T. vaginalis (Fig. 2).
4. Discussion
Within this investigation, we isolated and identiﬁed amaur-
ocine, a protein from fermentations of the mushroom
A. camerarium. Amaurocine inhibited T. vaginalis, and displayed a
proinﬂammatory character. Searches performed against NCBI
database presented similarity of some amaurocine peptides to
enzymes from A. dermatitidis ATP-dependent RNA helicase MAK5.
These helicases were described to be involved in post-
transcriptional and translational processes, such as in translation
and pre-mRNA (Wassarman and Steitz, 1991).
Mushrooms occur in most terrestrial ecosystems and are source
of several compounds such as terpenes, steroids, gamma-pyronesand phenolic acids, as well as proteins and polysaccharides of
medical importance. Immunomodulatory, antitumor, antiviral,
antiparasitic and antibacterial properties have been attributed to
those substances (Wasser and Weiss, 1999; Lindequist et al., 2005).
Amauroderma camerarium is a saprophytic fungus which grows in
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belongs to the family Ganodermataceae, being related to the me-
dicinal genus Ganoderma, used against hypertension, arthritis,
diabetes, hipercolesteromia, hepatitis, cardiovascular disease,
nephritis, dysmenorrhea, and lupus (Eo et al., 1999; Zhou et al.,
2007) in many Asiatic countries. Regarding the genus Amaur-
oderma, a study showed an anti-cancer effect in vivo from Amaur-
oderma rude fruiting bodies extracts and a second one described
Amauroderma rugosum products as potential therapeutic agents or
adjuvants in the management of inﬂammatory disorders (Jiao et al.,
2013; Chan et al., 2013). Nevertheless, the active compounds of
those investigations remain to be clariﬁed. To our knowledge, there
is no literature available about bioactive molecules produced by A.
camerarium.
A number of antiparasitc compounds from mushrooms were
isolated and identiﬁed, and some examples are lanostanes from
Ganoderma lucidum fruiting bodies, which showed anti-plasmodial
activity, 5-heptadeca-80Z,110Z,16-trienylresorcinol, from Merulius
incarnatus, an anti-Leishmania compound (Adams et al., 2010; Jin
and Zjawiony, 2006) and hypnophilin, extracted from Lentinus
strigosus fermentations, with trypanocidal activity (Cota et al.,
2008). Furthermore, similar activities were demonstrated by the
amphibian peptides magainin 2, dermaseptin S3 and S4, buforin 2
and ranalexin 1CB (Zucca and Savoia, 2011). T. vaginalis inhibition
was achieved when dermaseptin S1 (22 mM) (Savoia et al., 2010)
and the tritrpticin peptides derived from porcine cathelicidin
(Infante et al., 2011) were employed. Additionally information
about those amphibian peptides, as well as their mode of action is
available on a review (Rivas et al., 2009).
As peptides show immunomodulatory effects, we further
investigated amaurocine for those properties, employing human
neutrophils in a NO release assay. Neutrophils belong to the poly-
morphonuclear leukocytes (PMNs) type of cells, comprising the
ﬁrst line of non-speciﬁc host defense mechanisms. Those phago-
cytes are the main defense cells in vaginal discharge in women
infected with T. vaginalis (Buchwald et al., 1992; Ryu et al., 2004;
Song et al., 2010). Reactive free radicals (ROS) are associated with
the microbicide activity of PMNs (Yadav et al., 2006). Accumulation
of NO together with leukotriene B4 (LTB4) e a neutrophil-activator
released by T. vaginalis e and several host signaling molecules
provides a rapid migration of neutrophils to the affected site (Shaio
and Lin, 1995; Park et al., 1997; Serhan and Savill, 2005). Our data
suggest that amaurocine exhibits a proinﬂammatory character,
since it increased neutrophils NO release, although being harmless
against this type of cells.
5. Conclusion
Amaurocine, a novel protein puriﬁed from A. camerarium fer-
mentations showed activity against T. vaginalis isolates. In addition,
this protein demonstrated low toxicity towards human neutrophils
and a pro-inﬂammatory character. Our data indicate that amaur-
ocine may produce a synergic action being directly cytotoxic
against the parasites and indirectly enhancing the host immune
response, improving the protection from this mucosal pathogen.
Further studies will be conducted to explain its mechanism of
action.
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